KR102425303B1 - 항-메탄생성 조성물 및 그것의 용도 - Google Patents

항-메탄생성 조성물 및 그것의 용도 Download PDF

Info

Publication number
KR102425303B1
KR102425303B1 KR1020177005268A KR20177005268A KR102425303B1 KR 102425303 B1 KR102425303 B1 KR 102425303B1 KR 1020177005268 A KR1020177005268 A KR 1020177005268A KR 20177005268 A KR20177005268 A KR 20177005268A KR 102425303 B1 KR102425303 B1 KR 102425303B1
Authority
KR
South Korea
Prior art keywords
delete delete
modified
release
statin
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177005268A
Other languages
English (en)
Korean (ko)
Other versions
KR20170041769A (ko
Inventor
마크 피멘텔
루치 마투르
스티브 칸저
빈스 와처
Original Assignee
세다르스-신나이 메디칼 센터
신세틱 바이오로직스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세다르스-신나이 메디칼 센터, 신세틱 바이오로직스, 인코퍼레이티드 filed Critical 세다르스-신나이 메디칼 센터
Publication of KR20170041769A publication Critical patent/KR20170041769A/ko
Application granted granted Critical
Publication of KR102425303B1 publication Critical patent/KR102425303B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020177005268A 2014-08-13 2015-08-13 항-메탄생성 조성물 및 그것의 용도 Active KR102425303B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462036948P 2014-08-13 2014-08-13
US62/036,948 2014-08-13
US201462043789P 2014-08-29 2014-08-29
US201462043649P 2014-08-29 2014-08-29
US62/043,649 2014-08-29
US62/043,789 2014-08-29
US201562141355P 2015-04-01 2015-04-01
US62/141,355 2015-04-01
PCT/US2015/045140 WO2016025762A1 (en) 2014-08-13 2015-08-13 Anti-methanogenic compositions and uses thereof

Publications (2)

Publication Number Publication Date
KR20170041769A KR20170041769A (ko) 2017-04-17
KR102425303B1 true KR102425303B1 (ko) 2022-07-25

Family

ID=55301332

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177005268A Active KR102425303B1 (ko) 2014-08-13 2015-08-13 항-메탄생성 조성물 및 그것의 용도

Country Status (12)

Country Link
US (5) US9956292B2 (enExample)
EP (1) EP3179983A4 (enExample)
JP (1) JP6667526B2 (enExample)
KR (1) KR102425303B1 (enExample)
CN (1) CN106687107B (enExample)
AU (1) AU2015301596B2 (enExample)
BR (1) BR112017002761A2 (enExample)
CA (1) CA2955666A1 (enExample)
IL (1) IL250568B (enExample)
MX (1) MX2017001971A (enExample)
RU (1) RU2697851C2 (enExample)
WO (1) WO2016025762A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590102B2 (en) 2015-04-01 2023-02-28 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
CA2903493C (en) 2013-03-15 2022-05-31 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
CA2955666A1 (en) 2014-08-13 2016-02-18 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
US10219518B2 (en) * 2015-09-18 2019-03-05 Environmental Intellectual Property, Inc. Inhibition of methanogenesis to control wood boring insects and pestilence
WO2017200876A1 (en) * 2016-05-19 2017-11-23 Synthetic Biologics, Inc. Anti-methanogenic compositions
WO2017223177A1 (en) * 2016-06-21 2017-12-28 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses
EP4190318A1 (en) * 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
TW201834711A (zh) * 2016-12-14 2018-10-01 美商寶珍那提公司 以tnf抑制劑治療胃腸道疾病
JP7150723B2 (ja) * 2016-12-14 2022-10-11 ビオラ・セラピューティクス・インコーポレイテッド 消化管疾病のインテグリン阻害薬による治療
US12102721B2 (en) 2017-01-26 2024-10-01 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
EP3641732A1 (en) * 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
BR112021004523A2 (pt) * 2018-09-10 2021-06-08 Argenta Innovation Limited formulações para liberação sustentada em dispositivos de administração
EP4041022A4 (en) * 2019-10-09 2023-11-01 R.P. Scherer Technologies, LLC NON-ANIMAL SOFT GEL CAPSULE FORMULATIONS, METHOD FOR THEIR PRODUCTION AND USE THEREOF
CA3201057A1 (en) 2020-12-08 2022-06-16 Mark Christopher LAY Improvements to devices and methods for delivery of substances to animals
WO2023069904A1 (en) * 2021-10-19 2023-04-27 Cedars-Sinai Medical Center Daily fasting methane to detect intestinal methanogen overgrowth and monitor treatment response
EP4451900A4 (en) * 2021-12-23 2025-04-30 Fonterra Co-Operative Group Ltd Use of lactic acid bacteria to improve feed efficiency
WO2024006531A1 (en) 2022-07-01 2024-01-04 Arkea Bio Corp. Compositions and methods for reducing deleterious atmospheric gas emissions from flooded ecosystems
WO2025036806A1 (en) * 2023-08-15 2025-02-20 Evonik Operations Gmbh An enteric coated hard shell capsule for delivery of a dosage form in the ileum and colon
US12448600B2 (en) 2023-08-24 2025-10-21 Synergraze Inc. Extraction of antimethanogenic compounds
US12281342B2 (en) 2023-08-24 2025-04-22 Synergraze Inc. Extraction of antimethanogenic compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055173A1 (en) 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
CN103142552A (zh) 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225202A (en) 1880-03-02 Clothes-slide
GB423083A (en) 1934-05-22 1935-01-24 Hugh Edwin Johnstone Peake Improvements in and relating to the manufacture of fermented beverages and medicinalpreparations
JPS60133852A (ja) 1983-12-23 1985-07-17 Zenkoku Shokubutsu Tanpaku Shokuhin Kyodo Kumiai 新規な納豆製品
DE3718638A1 (de) 1987-06-04 1988-12-22 Thomae Gmbh Dr K Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH03275630A (ja) 1990-03-23 1991-12-06 Hayashikane Sangyo Kk 肝機能改善剤及び肝機能改善食品又は飲料
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
DE69433645T2 (de) 1993-10-19 2005-03-10 Commonwealth Scientific And Industrial Research Organisation Methode zur verbesserung der nahrungsverwertung von wiederkäuern oder wiederkäuer-ähnlichen tieren
US5447850A (en) 1994-01-31 1995-09-05 Mccann; James L. Method of producing methane from organic waste
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
JP3010007B2 (ja) 1995-05-22 2000-02-14 ビオフェルミン製薬株式会社 配合下剤
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
GB9711962D0 (en) 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
CN1119154C (zh) 1998-01-20 2003-08-27 上海信谊药业有限公司 双歧三联活菌制剂及制备方法
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
US5985907A (en) 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
US6328959B1 (en) 1998-09-18 2001-12-11 The United States Of America As Represented By The Secretary Of The Navy Intestinal hydrogen removal using hydrogen-metabolizing microbes
AU2161000A (en) * 1998-12-07 2000-06-26 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
CA2389616A1 (en) 1999-11-03 2001-05-10 Howard J. Smith & Associates Pty Ltd. Liver selective therapy
IL149524A0 (en) 1999-11-08 2002-11-10 Andrx Corp HMG-CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATIONS
AU2001269015B2 (en) 2000-06-13 2004-10-14 Unilever Plc Non-viable lactobacillus containing food product
US6299774B1 (en) 2000-06-26 2001-10-09 Jack L. Ainsworth Anaerobic digester system
US7098239B2 (en) * 2001-06-20 2006-08-29 Merck & Co., Inc Dipeptidyl peptidase inhibitors for the treatment of diabetes
DE60336128D1 (de) * 2002-05-20 2011-04-07 Cedars Sinai Medical Ct Los Angeles Its durch modulation der methankonzentration im darm
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
CA2492805C (en) 2002-07-18 2015-05-12 Agricultural Research Council Megasphaera elsdenii strain and its uses
ZA200501508B (en) 2002-09-03 2006-10-25 Biovail Lab Inc Pharmaceuticals formulations and methods for modified release of statin drugs
US20040132806A1 (en) * 2002-09-03 2004-07-08 Jackie Butler Pravastatin pharmaceutical formulations and methods of their use
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
US20070280949A1 (en) 2003-07-10 2007-12-06 Michelle Alfa Combination Therapy for Gastroenteric Diseases Caused by Microorganisms
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
AU2003289546A1 (en) 2003-12-16 2005-07-05 Uk Chemipharm Co., Ltd. Process for preparing simvastatin.
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
AU2005247195A1 (en) 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
US20060111436A1 (en) 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US20090233888A1 (en) 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
EP1861490A4 (en) 2005-03-23 2010-11-17 Univ St Louis USE OF ARRAYS TO MODULATE NUTRIENT CAPTURE FUNCTIONS BY THE GASTROINTESTINAL MICROBIOTE
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
WO2008151032A2 (en) 2007-05-31 2008-12-11 Washington University In St. Louis Arrays and methods comprising m. smithii gene products
JP5546451B2 (ja) * 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US7970905B2 (en) 2008-07-03 2011-06-28 International Business Machines Corporation Method, system and computer program product for server selection, application placement and consolidation planning of information technology systems
CN102369275A (zh) 2009-02-02 2012-03-07 卓莫赛尔公司 新型细胞系和方法
UY32802A (es) 2009-07-23 2011-01-31 Provimi Holding B V Composiciones para reducir la metanogénesis gastrointestinal en rumiantes
US20130230498A1 (en) 2010-02-16 2013-09-05 Arizona Board Of Regents For And On Behalf Of Arizona State University Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
CN103230593A (zh) * 2012-10-30 2013-08-07 辽宁亿灵科创生物医药科技有限公司 一种治疗胃肠疾病的药物组合物
AU2014205553A1 (en) * 2013-01-08 2015-07-09 Volant Holdings Gmbh Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
CA2903493C (en) 2013-03-15 2022-05-31 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
CA2955666A1 (en) 2014-08-13 2016-02-18 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
WO2017223177A1 (en) 2016-06-21 2017-12-28 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055173A1 (en) 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
CN103142552A (zh) 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590102B2 (en) 2015-04-01 2023-02-28 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Also Published As

Publication number Publication date
AU2015301596B2 (en) 2020-04-16
US20160045604A1 (en) 2016-02-18
US10668159B2 (en) 2020-06-02
RU2017106896A3 (enExample) 2019-03-19
BR112017002761A2 (pt) 2017-12-19
KR20170041769A (ko) 2017-04-17
IL250568A0 (en) 2017-03-30
US20200323781A1 (en) 2020-10-15
CA2955666A1 (en) 2016-02-18
RU2017106896A (ru) 2018-09-13
EP3179983A4 (en) 2018-01-10
US20190328885A1 (en) 2019-10-31
US9956292B2 (en) 2018-05-01
CN106687107B (zh) 2020-12-25
US20180289816A1 (en) 2018-10-11
EP3179983A1 (en) 2017-06-21
JP6667526B2 (ja) 2020-03-18
US10328151B2 (en) 2019-06-25
US20230036151A1 (en) 2023-02-02
RU2697851C2 (ru) 2019-08-21
JP2017528516A (ja) 2017-09-28
WO2016025762A1 (en) 2016-02-18
MX2017001971A (es) 2017-09-15
AU2015301596A1 (en) 2017-02-02
US11344501B2 (en) 2022-05-31
IL250568B (en) 2021-05-31
CN106687107A (zh) 2017-05-17

Similar Documents

Publication Publication Date Title
US20230036151A1 (en) Anti-methanogenic compositions and uses thereof
US20230398093A1 (en) Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US20200390742A1 (en) Clinically efficacious anti-methanogenic compositions and uses
JP7651620B2 (ja) 経口リファマイシンｓｖ組成物
EP3024461B1 (en) A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US20190277833A1 (en) Anti-methanogenic compositions
HK40110949A (en) Oral rifamycin sv compositions
HK40110239A (en) Oral rifamycin sv compositions
WO2021058656A1 (en) Rifaximin liquid formulations
HK40036103A (en) Oral rifamycin sv compositions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4